Results 151 to 160 of about 1,577 (196)

Advances in IL-2 Family Cytokine-Based Cancer Therapies: Overcoming Challenges Through Molecular Engineering and Delivery Strategies. [PDF]

Immune Netw
An H, Oh J, Bae J.
europepmc   +1 more source

Antitumor Activity of an Immunocytokine Composed of an Anti-GD2 Antibody and the IL-15 Superagonist RLI

OncoImmunology, 2013
International audienceThe use of interleukin (IL)-15 or the IL-15 superagonist RLI as immunological adjuvants presents many advantages over that of IL-2, including a reduced toxicity and an improved efficacy.
Agnès Quéméner, Marie Vincent, Yannick Jacques   +2 more
exaly   +2 more sources

N-Glycan Engineering of a Plant-Produced Anti-CD20-hIL-2 Immunocytokine Significantly Enhances Its Effector Functions

Biotechnology and Bioengineering, 2018
Anti-CD20 recombinant antibodies are among the most promising therapeutics for the treatment of B-cell malignancies such as non-Hodgkin lymphomas. We recently demonstrated that an immunocytokine (2B8-Fc-hIL2), obtained by fusing an anti-CD20 scFv-Fc ...
Eugenio Benvenuto, Anna Maria Salzano, Marcello Donini   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Immunocytokines

Melanoma Research, 1997
Targeted interleukin-2 (IL-2) therapy with immunocytokines (i.e. antibody-cytokine fusion proteins) is effective in eradicating established hepatic and pulmonary metastases of melanoma in animal model systems. The effector mechanisms responsible for this antitumor effect in syngeneic, immunocompetent mice involves mainly CD8+ T cells.
R A, Reisfeld, J C, Becker, S D, Gillies
openaire   +2 more sources

Facts and Hopes: Immunocytokines for Cancer Immunotherapy

Clinical Cancer Research, 2023
Abstract The clinical development of cytokines as cancer therapeutics has been limited due to significant toxicities generally observed with systemic administration. This narrow therapeutic window, together with relatively modest efficacy, has made natural cytokines unattractive drug candidates.
Aliyah Pabani, Justin F. Gainor
openaire   +2 more sources

Highly Potent Anti-CD20-RLI Immunocytokine Targeting Established Human B Lymphoma in SCID Mouse

MAbs, 2014
International audienceRituximab (RTX), a chimeric IgG1 monoclonal antibody directed against the CD20 antigen, has revolutionized the treatment of B-cell alignancies. Nevertheless, the relapsed/refractory rates are still high. One strategy to increase the
Laure Garrigue-antar, Laurie Lajoie, Agnès Quéméner   +2 more
exaly   +2 more sources